Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
2002 3
2003 6
2004 8
2005 18
2006 21
2007 32
2008 33
2009 35
2010 59
2011 68
2012 75
2013 65
2014 55
2015 50
2016 53
2017 57
2018 59
2019 57
2020 66
2021 65
2022 62
2023 46
2024 58
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

928 results

Results by year

Filters applied: . Clear all
Page 1
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer.
Sung C, An J, Lee S, Park J, Lee KS, Kim IH, Han JY, Park YH, Kim JH, Kang EJ, Hong MH, Kim TY, Lee JC, Lee JL, Yoon S, Choi CM, Lee DH, Yoo C, Kim SW, Jeong JH, Seo S, Kim SY, Kong SY, Choi JK, Park SR. Sung C, et al. Among authors: kim sy. Nat Cancer. 2023 Jun;4(6):844-859. doi: 10.1038/s43018-023-00572-5. Epub 2023 Jun 12. Nat Cancer. 2023. PMID: 37308678
Telemedicine: Current Impact on the Future.
Jin MX, Kim SY, Miller LJ, Behari G, Correa R. Jin MX, et al. Among authors: kim sy. Cureus. 2020 Aug 20;12(8):e9891. doi: 10.7759/cureus.9891. Cureus. 2020. PMID: 32968557 Free PMC article.
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study.
Krämer A, Bochtler T, Pauli C, Shiu KK, Cook N, de Menezes JJ, Pazo-Cid RA, Losa F, Robbrecht DG, Tomášek J, Arslan C, Özgüroğlu M, Stahl M, Bigot F, Kim SY, Naito Y, Italiano A, Chalabi N, Durán-Pacheco G, Michaud C, Scarato J, Thomas M, Ross JS, Moch H, Mileshkin L. Krämer A, et al. Among authors: kim sy. Lancet. 2024 Aug 10;404(10452):527-539. doi: 10.1016/S0140-6736(24)00814-6. Epub 2024 Jul 31. Lancet. 2024. PMID: 39096924 Free article. Clinical Trial.
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.
Oh DY, Maqueda MA, Quinn DI, O'Dwyer PJ, Chau I, Kim SY, Duran I, Castellano D, Berlin J, Mellado B, Williamson SK, Lee KW, Marti F, Mathew P, Saif MW, Wang D, Chong E, Hilger-Rolfe J, Dean JP, Arkenau HT. Oh DY, et al. Among authors: kim sy. BMC Cancer. 2023 Nov 3;23(1):1056. doi: 10.1186/s12885-023-11539-1. BMC Cancer. 2023. PMID: 37919668 Free PMC article. Clinical Trial.
Update on Recommendations for Surveillance for Children with Predisposition to Hematopoietic Malignancy.
Maese LD, Wlodarski MW, Kim SY, Bertuch AA, Bougeard G, Chang VY, Godley LA, Khincha PP, Kuiper RP, Lesmana H, McGee RB, McReynolds LJ, Meade J, Plon SE, Savage SA, Scollon SR, Scott HS, Walsh MF, Nichols KE, Porter CC. Maese LD, et al. Among authors: kim sy. Clin Cancer Res. 2024 Oct 1;30(19):4286-4295. doi: 10.1158/1078-0432.CCR-24-0685. Clin Cancer Res. 2024. PMID: 39078402 Review.
C-Reactive Protein Signaling Pathways in Tumor Progression.
Kim ES, Kim SY, Moon A. Kim ES, et al. Among authors: kim sy. Biomol Ther (Seoul). 2023 Sep 1;31(5):473-483. doi: 10.4062/biomolther.2023.132. Epub 2023 Aug 11. Biomol Ther (Seoul). 2023. PMID: 37562952 Free PMC article. Review.
928 results